文献速递乳腺癌放疗

乳房切除术后放疗与未接受化疗的T3N0乳腺癌患者总生存改善相关

Post-mastectomy radiotherapy is associated with improved overall survival in T3N0 patients who do not receive chemotherapy.
PubMed 文献 · Radiother Oncol · 2020-02-14

该回顾性匹配队列分析基于美国国家癌症数据库(NCDB)2006–2014年数据,纳入13,901例T3N0乳腺癌患者,比较乳房切除术后放疗(PMRT)与单纯乳房切除(MTX)的总生存(OS)。在pT3N0且未接受辅助化疗(AC)的患者中,PMRT与更高的7年OS相关(74% vs 65%,P<0.001;HR 0.78,95%CI 0.68–0.89,P<0.001);在接受AC或新辅助化疗(NAC)的患者中未见OS获益。

要点

  • pT3N0未接受AC者,PMRT组7年OS为74%,MTX组为65%(P<0.001)。
  • 双稳健多变量分析示PMRT与OS改善相关(HR 0.78,95%CI 0.68–0.89,P<0.001)。
  • 接受AC或NAC的T3N0患者中,PMRT未显示OS获益。

核心结论

  • PMRT改善pT3N0乳腺癌患者OS,但获益似乎仅限于未接受AC者。
  • 接受NAC的cT3N0患者中PMRT未改善OS,但对化疗反应不佳者可能存在获益。

研究设计与样本

  • 基于NCDB的回顾性匹配队列分析,纳入2006–2014年pT3N0未接受NAC或cT3N0接受NAC的乳腺癌患者。
  • 采用倾向评分逆概率治疗加权(IPTW)稳定权重匹配所有可用基线特征,共识别13,901例 eligible 患者。

主要发现

  • pT3N0队列中,MTX组中位随访47个月,PMRT组50个月。
  • cT3N0队列中,MTX组中位随访44个月,PMRT组46个月。
  • pT3N0患者PMRT组7年OS为74%,MTX组为65%(P<0.001)。
  • 双稳健多变量分析显示PMRT与OS改善相关(HR 0.78,95%CI 0.68–0.89,P<0.001)。
  • NAC队列中PMRT未改变OS,7年OS MTX组78%、PMRT组79%;乳腺和淋巴结残留病变者PMRT有OS改善趋势(HR 0.70,95%CI 0.46–1.07)。

关键数值与推荐

  • pT3N0未接受AC者:PMRT组7年OS 74% vs MTX组65%,P<0.001;HR 0.78(95%CI 0.68–0.89),P<0.001。
  • 接受AC的T3N0患者:PMRT无获益。
  • NAC队列:PMRT组7年OS 79% vs MTX组78%;残留病变者HR 0.70(95%CI 0.46–1.07)。

临床怎么用

  • 对pT3N0且未接受辅助化疗的乳腺癌患者,可考虑PMRT以改善OS。
  • 对接受AC或NAC的T3N0患者,PMRT的OS获益未获证实,决策需个体化。
  • 对NAC后乳腺和淋巴结残留病变者,PMRT可能存在获益趋势,但需更长随访确认。

局限性

  • 回顾性分析,存在选择偏倚等固有局限。
  • NAC队列随访时间可能不足以对化疗后患者PMRT获益做出 definitive 结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: There is limited retrospective evidence addressing the utility of post-mastectomy radiotherapy (PMRT) in patients with T3N0 breast cancer. We performed a retrospective analysis of the National Cancer Database (NCDB) comparing overall survival (OS) in T3N0 patients treated with mastectomy alone (MTX) or with PMRT. MATERIALS AND METHODS: We performed a matched-cohort analysis of NCDB breast cancer patients with pT3N0 disease who did not receive NAC, or cT3N0 patients who received NAC treated between 2006 and 2014. Patients were matched for all available baseline characteristics using propensity scores with inverse probability of treatment weighting (IPTW) with stabilized weights. RESULTS: We identified 13,901 eligible patients. In the pT3N0 cohort, median follow-up was 47 months for the MTX group and 50 months for the PMRT group. In the cT3N0 cohort, median follow-up was 44 months for the MTX group and 46 months for the PMRT group. OS was higher in pT3N0 patients treated with PMRT compared to MTX: 7-year OS of 74% vs. 65% (P < 0.001). Doubly robust multivariable analysis showed an association between PMRT and improved OS (HR 0.78, 95% CI 0.68-0.89, P < 0.001). There was no benefit to PMRT in patients who received adjuvant chemotherapy (AC). In the NAC cohort, PMRT did not change OS, with 7-year OS of 78% with MTX and 79% with PMRT. There was a trend of improved OS with PMRT in patients with residual disease in the breast and lymph nodes (HR 0.70, 95% CI 0.46-1.07). CONCLUSION: PMRT improves OS in patients with pT3N0 disease, but the benefit appears limited to those who do not receive AC. PMRT does not improve OS in patients with cT3N0 disease who receive NAC, but there might be a benefit in patients with a poor response to chemotherapy. However, longer follow-up may be needed to make a definitive conclusion about the benefit of PMRT in patients who receive chemotherapy.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Almahariq MF, Quinn TJ, Siddiqui ZA, et al. Post-mastectomy radiotherapy is associated with improved overall survival in T3N0 patients who do not receive chemotherapy. Radiother Oncol. 2020. PMID: 32065903. doi:10.1016/j.radonc.2020.01.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。